Clinical Trial Update: Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase I trial of DOTAP-based liposome delivering Cholesterol-Fus1 in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOTAP Cholesterol-Fus1 liposome (Cholesterol-Fus1 liposome formulated with DOTAP)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED